Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies

mAbs

Volumn 5, Issue 5, 2013, Pages 723-735

  Rafiq, Sarwish ^a   Siadak, Anthony ^b   Butchar, Jonathan P ^a   Cheney, Carolyn ^a   Lozanski, Gerard ^a   Jacob, Naduparambil K ^a   Lapalombella, Rosa ^a   McGourty, Jackie ^b   Moledor, Meghan ^b   Lowe, Richard ^b   Setter, Ben ^b   Jones, Jeffrey ^a   Flynn, Joseph M ^a   Andritsos, Leslie ^a   Devine, Steven ^a   Mo, Xiaokui ^a   Jarjoura, David ^a   Tridandapani, Susheela ^a   Algate, Paul ^b   Byrd, John C ^a   Muthusamy, Natarajan ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b Emergent Product Development   (United States)

Author keywords

ALL; CD37; CLL; Protein Therapeutics

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CD37 ANTIGEN; GAMMA INTERFERON; RITUXIMAB; TRASTUZUMAB; TRU 016; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG PROTEIN BINDING; EFFECTOR CELL; GLYCOSYLATION; NATURAL KILLER CELL; PROTEIN EXPRESSION;

ALL; CD37; CLL; PROTEIN THERAPEUTICS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACROPHAGES; PHAGOCYTOSIS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TETRASPANINS; TUMOR CELLS, CULTURED;

EID: 84883883781     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25282     Document Type: Article

References (47)

1. Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 1988; 140:905-14; PMID:3257508
2. Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 1986; 137:3013-8; PMID:3489782
3. Barrena S, Almeida J, Yunta M, López A, Fernández- Mosteirín N, Giralt M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005; 19:1376-83; PMID:15931266; http://dx.doi.org/10.1038/sj.leu.2403822
4. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7:1027-38; PMID:2666588
5. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10:1696-711; PMID:1403053
6. Brown RS, Kaminski MS, Fisher SJ, Chang AE, Wahl RL. Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl Med Biol 1997; 24:657-63; PMID:9352537; http://dx.doi.org/10.1016/S0969-8051(97)00099-1
7. Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011; 118:4159-68; PMID:21795744; http://dx.doi.org/10.1182/blood-2011-04-351932
8. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, et al. Targeting CD37- positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110:2569-77; PMID:17440052; http://dx.doi. org/10.1182/blood-2006-12-062927
9. Furman R, Andritsos L, Flinn IW, Forero-Torres A, Foon KA, Pagel JM, et al. Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL. [ASH Annual Meeting Abstracts]. Blood 2010; 116:56; https://ash. confex.com/ash/2010/webprogram/Paper32343.html.
10. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via lowaffinity activating Fcgamma receptors. Cancer Res 2007; 67:8882-90; PMID:17875730; http://dx.doi. org/10.1158/0008-5472.CAN-07-0696
11. Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 2005; 65:7934-41; PMID:16140965
12. Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50:1361-8; PMID:19562616; http://dx.doi. org/10.1080/10428190903026500
13. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006; 12:2879-87; PMID:16675584; http://dx.doi.org/10.1158/1078-0432.CCR-05-2619
14. Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 2009; 9:58; PMID:19226457; http://dx.doi.org/10.1186/1471-2407-9-58
15. Saul R, Molyneux RJ, Elbein AD. Studies on the mechanism of castanospermine inhibition of alphaand beta-glucosidases. Arch Biochem Biophys 1984; 230:668-75; PMID:6424575; http://dx.doi. org/10.1016/0003-9861(84)90448-X
16. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
17. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10. 1200/JCO.2003.05.013
18. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-9; PMID:12571855; http://dx.doi.org/10.1002/art.10764
19. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004; 103:1472-4; PMID:14563637; http://dx.doi. org/10.1182/blood-2003-07-2548
20. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, et al. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009; 23:912-8; PMID:19225537; http://dx.doi.org/10.1038/leu.2008.385
21. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012; 21:694-708; PMID:22624718; http://dx.doi.org/10.1016/ j.ccr.2012.03.040
22. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201
23. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69; PMID:15210744; http://dx.doi.org/10.1084/jem.20040119
24. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335:213-22; PMID:20605905; http://dx.doi.org/10.1124/jpet.110.168062
25. Tedder TF, Baras A, Xiu Y. Fcgamma receptordependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 2006; 28:351-64; PMID:17091246; http://dx.doi.org/10.1007/s00281-006-0057-9
26. Wang ZQ, Bapat AS, Rayanade RJ, Dagtas AS, Hoffmann MK. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology 2001; 102:331-7; PMID:11298832; http://dx.doi. org/10.1046/j.1365- 2567.2001.01171.x
27. Ashraf SQ, Umana P, Mössner E, Ntouroupi T, Brünker P, Schmidt C, et al. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009; 101:1758-68; PMID:19904275; http://dx.doi. org/10.1038/sj.bjc.6605355
28. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27:321-7; PMID:6169660; http://dx.doi.org/10.1002/ijc.2910270310
29. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011; 25:101-9; PMID:20975664; http://dx.doi. org/10.1038/leu.2010.240
30. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi. org/10.1073/pnas.0508123103
31. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
32. Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp Cell Res 2011; 317:1278-85; PMID:21459085; http://dx.doi.org/10.1016/j. yexcr.2011.03.018
33. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995; 5:813-22; PMID:8720080; http://dx.doi. org/10.1093/glycob/5.8.813
34. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87:614-22; PMID:15352059; http://dx.doi.org/10.1002/bit.20151
35. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, et al. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 2007; 44:3122-31; PMID:17379311; http://dx.doi.org/10.1016/j. molimm.2007.02.005
36. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11:2327-36; PMID:15788684; http://dx.doi.org/10.1158/1078-0432.CCR-04-2263
37. Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. [v.]. Hematol Oncol Clin North Am 2009; 23:949-71, v; PMID:19825447; http://dx.doi. org/10.1016/j.hoc.2009.07.005
38. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004; 18:1557-8; PMID:15229619; http://dx.doi.org/10.1038/sj.leu.2403422
39. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006; 106:2645-51; PMID:16688777; http://dx.doi. org/10.1002/cncr.21901
40. Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood 2010; 116:5930-40; PMID:20844239; http://dx.doi.org/10.1182/blood-2010-01-262006
41. Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011; 52:325-7; PMID:21077738; http://dx.doi.org/10.3109/10428194.2010.529206
42. Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009; 23:806-7; PMID:18971949; http://dx.doi. org/10.1038/leu.2008.303
43. Keating M, Cheson B, Gribben JG, Robertson B, Nadler L. Innovative strategies for the treatment of CLL. Leuk Lymphoma 1996; 22(Suppl 2):53-64; PMID:9021709; http://dx.doi. org/10.3109/10428199609102703
44. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108:1334-8; PMID:16670263; http://dx.doi.org/10.1182/blood-2005-12-011213
45. Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012; 26:1720-2; PMID:22333878; http://dx.doi. org/10.1038/leu.2012.40
46. Pan X, Jarjoura D. Robust Estimation of the Variance of a Contrast in Linear Mixed Models. Joint Statistical Meetings 2009.
47. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6:65-70